Now the question is whether NVS/MNTA will sue Amphastar for patent infringement to try to block Amphastar from launching generic Lovenox. To my knowledge, Amphastar is not a defendant in NVS/MNTA’s suit against Teva.
p.s. The above assumes that Amphastar's approval is for a substitutable generic Lovenox. If the approved product is not substitutable for branded Lovenox, then there is no significant economic harm to NVS/MNTA.
Momenta Pharma (MNTA) Shares Sink as Amphastar Pharma Gets FDA Approval for Generic Lovenox -WSJ
More News related to MNTA
Momenta Pharma (MNTA) Shares Sink as Amphastar Pharma Gets FDA Approval for Generic Lovenox -WSJ
Momenta Pharma (MNTA) Shares Sink as Amphastar Pharma Gets FDA Approval for Generic Lovenox -WSJ Prana (PRAN) Reports Publication of Positive Data for PBT2 on Restoring Cognitive Function in Alzheimer's Patients Aastrom (ASTM) Reports Encouraging Results of IMPACT-DCM from 12-Month Follow Up Marshall Edwards (MSHL) Doses First Patient in ME-143 Phase I Adeona (AEN) Completes Enrollment in Trimesta Trial; Receives Additional Funding
More News related to FDA September 19, 2011 11:18 AM EDT
Shares of Momenta Pharma (Nasdaq: MNTA) are plunging following a WSJ headline which reports Amphastar Pharma has received FDA approval for the generic version of Lovenox.
Market Data 
Markets 
AI
